EPSILOGEN
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
EPSILOGEN
Social Links:
Industry:
Biopharma Biotechnology Genetics Life Science Therapeutics
Founded:
2016-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.epsilogen.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0) 203 657 7612
Email Addresses:
[email protected]
Total Funding:
39.95 M GBP
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS MailChannels UKFast.Net
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Arbor Biotechnologies
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Bicara Therapeutics
Bicara Therapeutics is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology.
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Erasca
Erasca is a developer of oncology drugs intended to provide precision oncology options.
Genomics
Genomics plc aiming to lead the genomic transformation of healthcare.
PhagoMed
PhagoMed is a developer of a biotech platform designed to develop drugs and therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Epidarex Capital
Epidarex Capital investment in Series B - Epsilogen
ALSA Ventures
ALSA Ventures investment in Series B - Epsilogen
British Patient Capital
British Patient Capital investment in Series B - Epsilogen
Schroders Capital
Schroders Capital investment in Series B - Epsilogen
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Epsilogen
Caribou Property
Caribou Property investment in Series B - Epsilogen
3B Future Health Fund
3B Future Health Fund investment in Series B - Epsilogen
Innovate UK
Innovate UK investment in Grant - Epsilogen
AlbionVC
AlbionVC investment in Series A - Epsilogen
Epidarex Capital
Epidarex Capital investment in Series A - Epsilogen
Official Site Inspections
http://www.epsilogen.com Semrush global rank: 5.16 M Semrush visits lastest month: 1.57 K
- Host name: 1109826.cloudwaysapps.com
- IP address: 104.248.174.226
- Location: London United Kingdom
- Latitude: 51.5353
- Longitude: -0.6658
- Timezone: Europe/London
- Postal: SL1
